Jacob van Naarden, Chief Business Officer at Loxo Oncology, Inc. (LOXO), sold 5,300 shares at $167.39 ($883K) on 2018-09-12, disclosed to the SEC on 2018-09-14.
Open-market sale of $883k LOXO by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $164.44 | 756 | $124K | 14.1% |
| 2 | $165.32 | 1,885 | $312K | 35.3% |
| 3 | $166.74 | 1,059 | $177K | 20.0% |
| 4 | $167.39 | 1,000 | $167K | 19.0% |
| 5 | $171.03 | 600 | $103K | 11.6% |
| Total | $166.52 avg | 5,300 |
| $883K |
| 100% |
| Filing → |
| LOXO | SELL | 2018-12-12 | $426K | — | Filing → |
| LOXO | SELL | 2018-12-12 | $120K | — | Filing → |
| LOXO | SELL | 2018-11-28 | $1.5M | — | Filing → |